Literature DB >> 30211314

Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults.

Luisa M Arellano1, Sukeshi Patel Arora1.   

Abstract

Over the past 30 years, the incidence in of hepatocellular carcinoma (HCC) in the United States has tripled, largely due to untreated chronic Hepatitis C virus, alcoholic hepatitis, and non-alcoholic steatohepatitis (NASH). Additionally, the incidence of HCC among South Texas Hispanics is higher than elsewhere in the United States. The median age of HCC is 62 years in United States and 67 years in South Texas, with over 30% being 70 years of age or older. However, there is limited data on how to treat older adults with advanced HCC. In this review, we will discuss treatment options for older adults with advanced HCC, further emphasizing the need for prospective studies in this population.

Entities:  

Keywords:  hepatocellular carcinoma; older adult; sorafenib; targeted therapy; treatment options

Year:  2018        PMID: 30211314      PMCID: PMC6130815     

Source DB:  PubMed          Journal:  J Nat Sci        ISSN: 2377-2700


  26 in total

1.  Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.

Authors:  Hanna K Sanoff; Allison M Deal; Janakiraman Krishnamurthy; Chad Torrice; Patrick Dillon; Jessica Sorrentino; Joseph G Ibrahim; Trevor A Jolly; Grant Williams; Lisa A Carey; Amy Drobish; Brittaney-Belle Gordon; Shani Alston; Arti Hurria; Karin Kleinhans; K Lenhard Rudolph; Norman E Sharpless; Hyman B Muss
Journal:  J Natl Cancer Inst       Date:  2014-03-28       Impact factor: 13.506

Review 2.  The regulation of INK4/ARF in cancer and aging.

Authors:  William Y Kim; Norman E Sharpless
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

Review 3.  Overview of the MNA--Its history and challenges.

Authors:  B Vellas; H Villars; G Abellan; M E Soto; Y Rolland; Y Guigoz; J E Morley; W Chumlea; A Salva; L Z Rubenstein; P Garry
Journal:  J Nutr Health Aging       Date:  2006 Nov-Dec       Impact factor: 4.075

4.  Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.

Authors:  Ghassan K Abou-Alfa; Tim Meyer; Ann-Lii Cheng; Anthony B El-Khoueiry; Lorenza Rimassa; Baek-Yeol Ryoo; Irfan Cicin; Philippe Merle; YenHsun Chen; Joong-Won Park; Jean-Frederic Blanc; Luigi Bolondi; Heinz-Josef Klümpen; Stephen L Chan; Vittorina Zagonel; Tiziana Pressiani; Min-Hee Ryu; Alan P Venook; Colin Hessel; Anne E Borgman-Hagey; Gisela Schwab; Robin K Kelley
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

5.  Ink4a/Arf expression is a biomarker of aging.

Authors:  Janakiraman Krishnamurthy; Chad Torrice; Matthew R Ramsey; Grigoriy I Kovalev; Khalid Al-Regaiey; Lishan Su; Norman E Sharpless
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

6.  Hepatocellular carcinoma incidence, mortality, and survival trends in the United States from 1975 to 2005.

Authors:  Sean F Altekruse; Katherine A McGlynn; Marsha E Reichman
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Incidence and risk factors for hepatocellular carcinoma in Texas Latinos: implications for prevention research.

Authors:  Amelie G Ramirez; Nancy S Weiss; Alan E C Holden; Lucina Suarez; Sharon P Cooper; Edgar Munoz; Susan L Naylor
Journal:  PLoS One       Date:  2012-04-18       Impact factor: 3.240

9.  BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.

Authors:  Scott M Wilhelm; Christopher Carter; Liya Tang; Dean Wilkie; Angela McNabola; Hong Rong; Charles Chen; Xiaomei Zhang; Patrick Vincent; Mark McHugh; Yichen Cao; Jaleel Shujath; Susan Gawlak; Deepa Eveleigh; Bruce Rowley; Li Liu; Lila Adnane; Mark Lynch; Daniel Auclair; Ian Taylor; Rich Gedrich; Andrei Voznesensky; Bernd Riedl; Leonard E Post; Gideon Bollag; Pamela A Trail
Journal:  Cancer Res       Date:  2004-10-01       Impact factor: 13.312

10.  Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults.

Authors:  Hui Guo; Tao Wu; Qiang Lu; Jian Dong; Yi-Fan Ren; Ke-Jun Nan; Yi Lv; Xu-Feng Zhang
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

View more
  4 in total

Review 1.  Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology.

Authors:  Sukeshi Patel Arora; Gabor Liposits; Susan Caird; Richard F Dunne; Gordon Taylor Moffat; David Okonji; Maria Grazia Rodriquenz; Divyanshu Dua; Efrat Dotan
Journal:  J Geriatr Oncol       Date:  2019-11-06       Impact factor: 3.599

2.  Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.

Authors:  Guilherme Nader Marta; Leonardo G da Fonseca; Maria Ignez Braghiroli; Fernando Moura; Paulo M Hoff; Jorge Sabbaga
Journal:  Clinics (Sao Paulo)       Date:  2021-01-22       Impact factor: 2.365

3.  Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.

Authors:  Min Deng; Lin Fang; Shao-Hua Li; Rong-Ce Zhao; Jie Mei; Jing-Wen Zou; Wei Wei; Rong-Ping Guo
Journal:  Mutagenesis       Date:  2021-10-06       Impact factor: 3.000

4.  Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.

Authors:  Xiaomin Wu; Xiaojing Zhang; Leilei Tao; Xichao Dai; Ping Chen
Journal:  Biomed Res Int       Date:  2020-07-15       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.